Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo
about
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesStructure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisKey roles of the OPG-RANK-RANKL system in bone oncologyComputational modeling of interactions between multiple myeloma and the bone microenvironmentFas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone lossMathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Rheumatic diseases: the effects of inflammation on bone.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Structure based antibody-like peptidomimetics.A virtual approach to evaluate therapies for management of multiple myeloma induced bone diseasePeptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling.Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study.Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell.Delivery of RANKL-Binding Peptide OP3-4 Promotes BMP-2-Induced Maxillary Bone Regeneration.Inhibition of the osteoclast activity with the application of recombinant murine RANK protein.Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation.
P2860
Q26863493-AED12993-ECDB-4DD8-8380-3892A77C0420Q27665673-E36B9351-3457-426F-81D6-227956B42580Q28287394-2C997727-A557-463E-AC88-178FCD6796B9Q28477867-3B4B14B8-7089-4794-A191-5E4C0C248E18Q33695961-B35A1A76-39F4-46B5-9BF5-0581C30B35D9Q33911557-5D9E2FE5-289E-4AFF-A1C3-CEDBB7E882BAQ34567407-BC6F3D38-8EA5-4D84-B88F-1C3E5AD5C875Q34806153-3CCD99D0-8A6B-4BD5-B9AE-078B13D3FE7BQ36324975-831FAF3B-0D81-415B-9E49-C44FACD40DB8Q36860987-6307C665-4BBB-42CF-9D4E-5859127F92F0Q37148681-C4429AED-DDCE-4359-9CA7-98827C493A6EQ37185494-AF2585B1-1390-4C74-95F7-D2E6E5D170B9Q39654548-6C43831A-0F04-43E2-95C6-9582BB28C8F3Q40093202-A115F815-A09C-42E6-9093-929C9B5571DFQ41989650-F8F86C7B-0300-4E30-B61A-6EE302D89B23Q42948793-8D4C2176-D52E-4FAD-97B2-1A532ED999B1Q44006640-21F7498C-0FB0-4209-ABE1-F6EF713EB5D4Q51422585-60CC0C72-BAFF-4BC1-860C-E536F376FC6DQ51573211-DF7873EE-8E51-470E-B990-3EC5B5B282EEQ51760981-0B064D28-7E6E-42F9-8659-64D761BCF03C
P2860
Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Disabling of receptor activato ...... ics restores bone loss in vivo
@ast
Disabling of receptor activato ...... ics restores bone loss in vivo
@en
Disabling of receptor activato ...... ics restores bone loss in vivo
@nl
type
label
Disabling of receptor activato ...... ics restores bone loss in vivo
@ast
Disabling of receptor activato ...... ics restores bone loss in vivo
@en
Disabling of receptor activato ...... ics restores bone loss in vivo
@nl
prefLabel
Disabling of receptor activato ...... ics restores bone loss in vivo
@ast
Disabling of receptor activato ...... ics restores bone loss in vivo
@en
Disabling of receptor activato ...... ics restores bone loss in vivo
@nl
P2093
P2860
P3181
P356
P1476
Disabling of receptor activato ...... ics restores bone loss in vivo
@en
P2093
Hongtao Zhang
Masa Kinosaki
Ramachandran Murali
Yongwon Choi
P2860
P304
P3181
P356
10.1074/JBC.M309690200
P407
P577
2003-12-15T00:00:00Z